Ask the doctor: What do you know about Prolia and Reclast for osteoporosis?
All three drugs suppress bone remodeling, increase bone density, and reduce the risk of fractures. Denosumab and zoledronic acid reduce fractures at both the spine and hip, but ibandronate reduces only spine fractures. Consequently, clinicians recommend ibandronate less often than two other bisphosphonates — alendronate (Fosamax) and risedronate (Actonel).
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
